Form 4: Summit Therapeutics CEO Boosts Stake in Private Placement

Summit Therapeutics Co-CEO Mahkam Zanganeh acquired over 14 million shares of common stock through a private placement at $18.74 per share.

Summary

• Mahkam Zanganeh, Co-Chief Executive Officer, Director, and 10% Owner of Summit Therapeutics Inc. (SMMT), reported significant acquisitions of common stock.
• The transactions occurred on October 21, 2025, as part of a private placement.
• Shares were acquired at a price of $18.74 per share.
• A total of 14,274,277 shares were acquired across various indirect holdings: 266,808 shares by the Mahkam Zanganeh Revocable Trust, 26,680 shares by an immediate family member, and 13,980,789 shares by a spouse.
• The transaction is anticipated to close on or about October 23, 2025.
• The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein.

Sentiment

Score: 8

Explanation: The significant insider buying by a Co-CEO, Director, and 10% owner, especially through a private placement, indicates strong confidence in the company's future prospects and valuation.

Positives

• Significant insider buying by a Co-CEO, Director, and 10% owner, indicating strong confidence in the company's future.
• The acquisition was part of a private placement, suggesting a structured investment by key stakeholders.
• The substantial investment at $18.74 per share demonstrates a belief in the company's valuation at this price point.

Future Outlook

The filing does not provide a future outlook beyond the anticipated closing date of the private placement transaction.

Industry Context

Insider buying, especially by a CEO and significant owner, often signals strong internal confidence in the company's prospects, potentially differentiating it from competitors or indicating a belief that the stock is undervalued relative to industry peers. This private placement could be part of a broader capital raise or strategic financing initiative for Summit Therapeutics.

Comparison to Industry Standards

• Insider purchases of this magnitude by a CEO and 10% owner are generally viewed positively, often exceeding typical insider transaction volumes.
• While specific comparable companies or projects are not mentioned in the filing, such a substantial investment suggests a strong belief in Summit Therapeutics' future performance, potentially outperforming industry benchmarks.

Related Party Transactions

• Acquisition of shares by an immediate family member and spouse of the reporting person as part of the private placement.
• Acquisition of shares by the Mahkam Zanganeh Revocable Trust and the Shaun Zanganeh Irrevocable Trust, where the reporting person is a trustee.

Stakeholder Impact

• Shareholders: The significant insider buying could be seen as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: Reinforces alignment of interests between executive leadership and shareholders.

Next Steps

• Anticipated closing of the private placement transaction on or about October 23, 2025.

Key Dates

Recommendation

The substantial insider buying by Co-CEO Mahkam Zanganeh, who is also a Director and 10% owner, through a private placement at $18.74 per share, signals strong conviction in Summit Therapeutics' future value and prospects. Such a significant investment by a key insider often precedes positive developments or indicates a belief that the stock is undervalued, making it an attractive 'buy' signal for seasoned investors.

Keywords

Summit Therapeutics, SMMT, Insider Buying, Private Placement, Mahkam Zanganeh, Common Stock, SEC Form 4, Equity Acquisition